Tatro Capital LLC Takes Position in Novo Nordisk A/S (NYSE:NVO)

Tatro Capital LLC acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 5,210 shares of the company’s stock, valued at approximately $341,000.

Other hedge funds also recently bought and sold shares of the company. TD Asset Management Inc. boosted its stake in shares of Novo Nordisk A/S by 4.0% during the 4th quarter. TD Asset Management Inc. now owns 96,275 shares of the company’s stock worth $5,572,000 after acquiring an additional 3,664 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its position in shares of Novo Nordisk A/S by 4.0% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 92,440 shares of the company’s stock valued at $5,350,000 after purchasing an additional 3,514 shares during the period. Chevy Chase Trust Holdings Inc. bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at about $63,000. Prospera Financial Services Inc raised its position in shares of Novo Nordisk A/S by 43.0% in the fourth quarter. Prospera Financial Services Inc now owns 13,061 shares of the company’s stock valued at $756,000 after purchasing an additional 3,930 shares during the period. Finally, Advisor Group Inc. raised its position in shares of Novo Nordisk A/S by 5.6% in the fourth quarter. Advisor Group Inc. now owns 33,981 shares of the company’s stock valued at $1,967,000 after purchasing an additional 1,794 shares during the period. 6.69% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts recently commented on NVO shares. Morgan Stanley reaffirmed an “equal weight” rating on shares of Novo Nordisk A/S in a research report on Monday, May 18th. BofA Securities lowered shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Monday. Societe Generale reaffirmed a “sell” rating on shares of Novo Nordisk A/S in a research report on Thursday, May 7th. Cowen started coverage on shares of Novo Nordisk A/S in a research report on Monday, May 4th. They set a “market perform” rating and a $72.00 price target on the stock. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Novo Nordisk A/S in a research report on Wednesday, May 13th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $174.00.

NVO stock traded up $0.16 during mid-day trading on Thursday, hitting $66.04. The stock had a trading volume of 8,153 shares, compared to its average volume of 1,412,398. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.05. Novo Nordisk A/S has a 52 week low of $47.24 and a 52 week high of $68.71. The firm has a market capitalization of $155.72 billion, a P/E ratio of 25.93, a P/E/G ratio of 2.51 and a beta of 0.45. The firm has a fifty day simple moving average of $65.50 and a 200 day simple moving average of $61.62.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, May 6th. The company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.68 by $0.07. Novo Nordisk A/S had a net margin of 31.91% and a return on equity of 73.87%. The firm had revenue of $5 billion for the quarter, compared to analyst estimates of $4.70 billion. As a group, equities analysts expect that Novo Nordisk A/S will post 2.69 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Story: Why is insider trading harmful?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.